These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9628279)

  • 21. [Recent molecular and pharmacologic aspects of ACE inhibitors].
    Köppel H; Eber B; Gasser R; Klein W
    Wien Med Wochenschr; 1995; 145(23):633-7. PubMed ID: 8578754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis].
    Divisón Garrote JA; Seguí Díaz M; Escobar Cervantes C
    Semergen; 2014 Oct; 40(7):399-400. PubMed ID: 25103068
    [No Abstract]   [Full Text] [Related]  

  • 23. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification.
    Maahs DM; Snell-Bergeon JK; Kinney GL; Wadwa RP; Garg S; Ogden LG; Rewers M
    J Diabetes Complications; 2007; 21(5):273-9. PubMed ID: 17825750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.
    White CM
    Pharmacotherapy; 1998; 18(3):588-99. PubMed ID: 9620109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes.
    Ruggenenti P; Remuzzi G
    Exp Nephrol; 1996; 4 Suppl 1():53-60. PubMed ID: 9001898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ACE-inhibitors: the indication spectrum grows wider].
    Fortschr Med Suppl; 1996; 178():1-10. PubMed ID: 9022411
    [No Abstract]   [Full Text] [Related]  

  • 30. [Subclinical albuminuria, microalbuminuria and proteinuria--accepted cardiovascular risk markers?].
    Schmieder RE; Schrader J; Zidek W; Tebbe U; Bramlage P; Paar WD; Böhm M
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2665-71. PubMed ID: 17109277
    [No Abstract]   [Full Text] [Related]  

  • 31. [Is it necessary to systematically treat diabetics with ACE inhibitors?].
    Marre M; Collet C; Stevenin C
    Journ Annu Diabetol Hotel Dieu; 2001; ():185-7. PubMed ID: 11565461
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyperkalemia and inhibitors of the renin-angiotensin-aldosterone system.
    Segal A
    N Engl J Med; 2004 Dec; 351(23):2450-1; author reply 2450-1. PubMed ID: 15575066
    [No Abstract]   [Full Text] [Related]  

  • 33. Current indications for ACE inhibitors and HOPE for the future.
    Burch S; Ou N
    Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Role of the endothelium in the control of vascular motility: physiologic aspects and physiopathologic implications in cardiovascular diseases].
    Limone P; Boeri E; Molinatti GM
    Minerva Med; 1993 Oct; 84(10):499-505. PubMed ID: 8247303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACP Journal Club. Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment.
    McCoy R; Smith S
    Ann Intern Med; 2014 Aug; 161(4):JC2. PubMed ID: 25133381
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations.
    Mancini GB
    Clin Invest Med; 2000 Apr; 23(2):144-61. PubMed ID: 10852664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New breakthrough for ACE inhibitors. HOPE Study: hope for all vascular patients?].
    MMW Fortschr Med; 1999 Oct; 141(42):66-7. PubMed ID: 10912112
    [No Abstract]   [Full Text] [Related]  

  • 38. Reversing endothelial dysfunction with ACE inhibitors. A new trend.
    Rajagopalan S; Harrison DG
    Circulation; 1996 Aug; 94(3):240-3. PubMed ID: 8759059
    [No Abstract]   [Full Text] [Related]  

  • 39. ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose?
    Pellizzer AM; Krum H
    Aust Fam Physician; 1996 Jul; 25(7):1067-9, 1072-3, 1076-7. PubMed ID: 8768273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.